PREVALENCE AND CHARACTERISTICS OF MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII CASES AT THE DR.WAHIDIN SUDIROHUSODO GENERAL HOSPITAL IN MAKASSAR
DOI:
https://doi.org/10.24293/ijcpml.v25i2.1363Keywords:
Acinetobacter baumannii, MDRAB, antibiotic resistanceAbstract
Multidrug-resistant Acinetobacter baumannii (MDRAB) is a strain that is resistant to three or more classes of antibiotics. As the prevalence of MDRAB increases, the antibiotics of choice become limited. Identification of MDRAB is required to manage and control infection. This research was conducted to determine the prevalence and characteristics of MDRAB in the Wahidin Sudirohusodo Hospital Makassar. This research was a retrospective study, conducted from January to December 2016. Bacterial identification and antimicrobial susceptibility testing (AST) were performed using VITEK 2. The patient data were obtained from the medical records. A total of 323 Acinetobacter baumannii isolates was obtained, consisting of 188 isolates in January-June 2016 and 36 of which were MDRAB (19.15%) with the average length-of-stay 33 days; and 135 isolates in July-December 2016 and 31 of which were MDRAB (22.96%) with the average length-of-stay 27 days. Multidrug-resistant Acinetobacter baumannii was mostly discovered from patients using three or more medical devices and on a single antibiotic therapy. Multidrug-resistant Acinetobacter baumannii isolates were mostly obtained from sputum and pus specimens, and the majority of patients had an infection and respiratory diseases. The most comorbid diseases in MDRAB were endocrine-metabolic diseases. The result of AST showed 100% and 96% susceptibility to Polymyxin B; 71.43% and 54.84% to Amikacin; 66.67% and 50% to Trimethoprim/Sulfamethoxazole, respectively. Prevalence of MDRAB in 2016 increased from January-June (19.15%) to July-December (22.96%), suggesting a need to identify patients at risk for MDRAB infection and to promote the rational use of antibiotics. Polymyxin B, Amikacin, and Trimethoprim/Sulfamethoxazole are the antibiotics of choice to treat MDRAB.
Downloads
References
Central for Disease Control and Prevention. Acinetobacter in Healthcare Settings [Online]. 2010 November 24 [cited 2017 July 29]. Available from : https://www.cdc.gov/hai/organisms/acinetobacter.html
World Health Organization. Multidrug-Resistant Acinetobacter baumannii (MDRAB) [Online]. 2010 November 1 [cited 2017 August 2]. Available from : http://www.wpro.who.int/mediacentre/factsheets/fs_20101102/en/
Cunha BA. Acinetobacter [Online]. 2016 March 15 [cited 2017 August 2]. Available from : http://emedicine.medscape.com/article/236891-overview
Antunes LCS, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathogens and Disease. 2014 (0):1-10.
Zarilli R, Pournaras S, Giannouli M, Tsakris A. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. International Journal of Antimicrobial Agents 41 (2013): 11-19.
Tuon FF, Rocha JL, Merlini AB. Combined therapy for multi-drug-resistant Acinetobacter baumannii infection – is there evidence outside the laboratory?. Journal of Medical Microbiology (2015), 64, 951-959.
Bigot S and Salcedo SP. The influence of two-partner secretion systems on the virulence of Acinetobacter baumannii. Virulence. 2017; 0(0): 1-2.
Maragakis LL, Perl TM. Acinetobacter baumannii: Epidemiology, Antimicrobial Resistance, and Treatment Options. Clinical Infectious Diseases 2008;46: 1254-63.
Hasan B, Perveen K, Olsen B and Zahra R. Emergence of carbapenem-resistant Acinetobacter baumannii in hospitals in Pakistan. Journal of Medical Microbiology (2014), 63 : 50-55.
Rahman V, Anggraini D, Fauziah D. Pola Resistensi Acinetobacter baumannii yang Diisolasi di Intensive Care Unit (ICU) RSUD Arifin Achmad Provinsi Riau Periode 1 Januari hingga 31 Desember 2014. Jurnal Online Mahasiswa FK (2015), 2:2.
Anggraini D, Yovi I, Rahayu PY. Gambaran Infeksi oleh Acinetobacter baumannii Resisten Meropenem di RSUD Arifin Achmad Provinsi Riau Periode 1 Januari – 31 Desember 2014 [Online]. 2014 [cited 2017 August 23]. Available from : https://www.scribd.com/document/346846276/ GAMBARAN-INFEKSI-OLEH-ACINETOBACTER-BAUMANNII-RESISTEN-MEROPENEM-DI-RSUD-ARIFIN-ACHMAD-PROVINSI-RIAU-PERIODE-01-JANUARI-2014-31-DESEMBER-2014
Torres HA, Vazquez EG, Yague G, Gomez JG. Multidrug resistant Acinetobacter baumannii: Clinical Update and New Highlights. Rev Esp Quimioter 2010;23(1):12-19.
Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, et al. Multidrug-resistant Acinetobacter Infection Mortality Rate and Length of Hospitalization. Emerging Infectious Diseases 2007;13(1): 97-103.
Cheah SE, Li J, Tsuji BT, Forrest A, Bulitta JB, Nation RL. Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance. Antimicrobial Agents and Chemotherapy 2016; 60(7): 3921-33.
Urban C, Mariano N, Rahal JJ. Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI21 and Cecropin P1. Antimicrobial Agents and Chemotherapy 2001; 45(3): 994-5.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.